Human papillomavirus (HPV) typing as an adjunct to cervical cancer screening

Cytopathology

Volumn 10, Issue 1, 1999, Pages 8-15

  Syrjanen K J ^a   Syrjanen S M ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CYTODIAGNOSIS; DEVELOPING COUNTRY; DISEASE COURSE; FEMALE; HUMAN; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; RELIABILITY; REVIEW; RISK FACTOR; SCREENING; SCREENING TEST; SECONDARY PREVENTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

DEVELOPING COUNTRIES; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; UTERINE CERVICAL NEOPLASMS;

EID: 0032938801     PISSN: 09565507     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2303.1999.00166.x     Document Type: Review

References (49)

1. 1 Syrjänen KJ. Natural history of genital human papillomavirus infections. In: Lacey C, ed. Papillomavirus Reviews. Current Research on Papillomaviruses. Leeds: Leeds Medical Information, Leeds University Press, 1996: 189-206.
2. 2 Syrjänen KJ. Biological behaviour of cervical intraepithelial neoplasia. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell Science, 1997: 93-108.
3. 3 Ponten J, Adami H-O, Bergström R et al. Strategies for global control of cervical cancer. Int J Cancer 1995; 60: 1-26.
4. 4 Franco EL. The sexually transmitted disease model for cervical cancer: incoherent epidemiologic findings and the role of misclassification of human papilloma virus infection. Epidemiology 1991; 2: 98-106.
5. 5 Cuzick J, Sasieni P, Singer A. Risk factors for invasive cervix cancer in young women. Eur J Cancer 1996; 32A: 836-41.
6. 6 Bosch FX, Munoz N, deSanjose S. Human papillomavirus and other risk factors for cervical cancer. Biomed Pharmacother 1997; 51: 268-75.
7. 7 IARC Monographs on the evaluation of carcinogenic risks to humans, Vol. 64. Papillomavirusus. Lyon: IARC, 1995: 1-409.
8. 8 Brinton LA. Epidemiology of cervical cancer. Overview. IARC Sci Publ 1992; 119: 3-23.
9. 9 Boyle P. Global burden of cancer. Lancet 1997; 349 (Suppl. II): 23-6.
10. 10 Franco E, Syrjänen K, de-Wolf C et al. New Developments in Cervical Cancer Screening and Prevention. Geneva, Switzerland, June 17-19. Workshop. Cancer Epidemiol Biomarkers Prev 1996; 5: 853-6.
11. 11 Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell Science, 1997.
12. 12 Miller AB. Evaluation of the impact of screening for cancer of the cervix. IARC Sci Publ 1986; 76: 149-60.
13. 13 Gustafsson L, Adami HO. Optimization of cervical cancer screening. Cancer Causes Control 1992; 3: 125-36.
14. 14 Hakama M. Screening for cervical cancer: experience from the Nordic countries. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell Science, 1997: 190-9.
15. 15 Parkin DM. The epidemiological basis for evaluating screening policies. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell Science, 1997: 51-69.
16. 16 Patnick J. Organization, monitoring and use of resources for screening programmes. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell Science, 1997: 181-4.
17. 17 Sigurdsson K. Quality assurance in cervical cancer screening: the Icelandic experience. Eur J Cancer 1995; 31A: 728-34.
18. 18 Koss LG. Performance of cytology in screening for precursor lesions and early cancer of the uterine cervix. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell Science, 1997: 147-50.
19. 19 Koss LG. Error rates in cervical cancer screening: causes and consequences. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell Science, 1997: 163-8.
20. 20 Shingleton HM, Patrick RL, Johnston WW, Smith RA. The current status of the Papanicolaou smear. CA Cancer J Clin 1995; 45: 305-20.
21. 21 Richart RM. Screening. The next century. Cancer 1995; 76: 1919-27.
22. 22 Cox IT. Clinical role of HPV testing. Obstet Gynecol Clin North Am 1996; 23: 811-51.
23. 23 Beral V, Day NE. Screening for cervical cancer: is there a place for incorporating tests for the human papillomavirus? IARC Sci Publ 1992; 263-9.
24. 24 Lörincz AT. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. J Obstet Gynaecol Res 1996; 22: 629-36.
25. 25 Kaufman RH, Adam E, Icenogle J et al. Relevance of human papillomavirus screening in management of cervical intraepithelial neoplasia. Am J Obstet Gynecol 1997; 176: 87-92.
26. 26 Syrjänen SM. Basic concepts and practical applications of recombinant DNA techniques in detection of human papillomavirus (HPV) infections. APMIS 1990; 98: 95-110.
27. 27 Gupta J, Gendelman HE, Naghashfar Z, Gupta P, Rosenshein N, Sawada E, Woodruff JD, Shah K. Specific identification of human papillomavirus type in cervical smears and paraffin sections by in situ hybridization with radioactive probes: a preliminary communication. Int J Gynecol Pathol 1985; 4: 211-8.
28. 35S-labeled human papillomavirus (HPV) DNA probes. J Virol Methods 1988; 19: 225-38.
29. 29 Herrington CS. Human papillomaviruses (HPV) in gynaecological cytology: from molecular biology to clinical testing. Cytopathology 1995; 6: 176-89.
30. 30 Lörincz A. Methods for DNA hybridization and their clinical applicability to human papillomavirus detection. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell Science, 1997: 325-37.
31. 31 Sun XW, Ferenczy A, Johnson D, Koulos JP, Lungu O, Richart RM, Wright TC. Evaluation of the hybrid capture human papillomavirus deoxyribonucleic acid detection test. Am J Obstet Gynecol 1995; 173: 1432-7.
32. 32 Nindl I, Zahm DM, Meijer CJLM, Walboomers JMM, Schneider A. Human papillomavirus detection in high-grade squamous intraepithelial lesions: comparison of hybrid capture assay with a polymerase chain reaction system. Diagn Microbiol Infect Dis 1995; 23: 161-4.
33. 33 Schneider A, Zahm DM, Kirchmayr R, Schneider VL. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection. Am J Obstet Gynecol 1996; 174: 1534-41.
34. 34 Syrjänen S, Syrjänen K. Human papillomavirus (HPV) infections of the genital tract. Clinical significance and diagnosis by PCR. In: Becker Y, Daral G, eds. Frontiers in Virololgy: Diagnosis of Human Viruses by Polymerase Chain Reaction (PCR) Technology. Heldelberg: Springer-Verlag, 1992: 185-207.
35. 35 Reid R, Greenberg MD, Lorincz A et al. Should cervical cytologic testing be augmented by cervicography or human papillomavirus deoxyribonucleic acid detection? Am J Obstet Gynecol 1991; 164: 1461-9.
36. 36 Meijer CJLM, Rozendaal L, van der Linden JC, Helmerhorst ThJM, Voorhorst FJ, Walboomers JMM. Human papillomavirus testing for primary cervical cancer screening. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford; Blackwell Science, 1997: 338-47.
37. 37 Rozendaal L, Walboomers JM, van-der-Linden JC, Voorhorst FJ, Kenemans P, Helmerhorst TJ, van-Ballegooijen M, Meijer CJ. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996; 68: 766-9.
38. 38 Sankaranarayanan R, Pisani P. Prevention measures in the third world: are they practical? In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell Science, 1997: 70-83.
39. 39 Sherman ME, Schiffman MH, Lörincz A. Use of papillomavirus typing for quality assurance of cytological diagnosis. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell Science, 1997: 360-3.
40. 40 Sherlaw-Johnson C, Gallivan S, Jenkins D, Jones MH. Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modelling. J Clin Pathol 1994; 47: 430-5.
41. 41 Sherlaw-Johnson C, Gallivan S, Jenkins D. Evaluating cervical cancer screening programmes for developing countries. Int J Cancer 1997; 72: 210-6.
42. 42 Cuzick J, Sasieni P. Estimates of the cost impact of introducing human papillomavirus testing into cervical screening programme. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell Science, 1997: 364-72.
43. 43 Orbell S, Crombie I, Robertson A, Johnston G, Kenicer M. Assessing the effectiveness of a screening campaign: who is missed by 80% cervical screening coverage? J R Soc Med 1995; 88: 389-94.
44. 44 Raffle AE, Alden B, Mackenzie EF. Six years' audit of laboratory workload and rates of referral for colposcopy in a cervical screening programme in three districts. BMJ 1990; 301: 907-11.
45. 45 Segnan N. Cervical cancer screening. Human benefits and human costs in the evaluation of screening programmes. Eur J Cancer 1994; 30A: 873-5.
46. 46 Jenkins D, Sherlaw-Johnson C, Gallivan S. Can papilloma virus testing be used to improve cervical cancer screening? Im J Cancer 1996; 65: 768-73.
47. 47 van Ballegooijen M, van den Akker-van Merle ME, Warmerdam PG, Meijer CJLM, Walboomers JMM, Habbema JDF. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the cost-effectiveness. Br J Cancer 1997; 76: 651-7.
48. 48 McGoogan E. Advantages and limitations of automated screening systems in developing and developed countries. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell Science, 1997: 317-22.
49. 49 Baille R, Barron P, Learmonth G. Towards a rational cervical cytology screening strategy. Case study of a peri-urban settlement. S Afr Med J 1995; 85: 30-33.